Literature DB >> 23527725

Expression of ADAM28 and IGFBP-3 genes in patients with colorectal cancer - a preliminary report.

E Nowakowska-Zajdel, U Mazurek, J Wierzgon, T Kokot, E Fatyga, E Ziolko, K Klakla, A Blazelonis, D Waniczek, L Glogowski, A Kozowicz, E Niedworok, M Muc-Wierzgon.   

Abstract

Adamalisynes (ADAMs) play an important role in inter-membrane interactions, cell adhesion and fusion processes and protein shedding from the cell surface. Many reports indicate that members of the ADAMs family are overexpressed in human cancer. The aim of the present study was to evaluate ADAM28 and Insulin Like Growth Factor Binding Protein-3 (IGFBP-3)) gene expression in colorectal carcinoma tissues with regard to the overweight or obese status of the patients using an oligonucleotide microarray technique. Fresh tissue specimens were obtained from colorectal cancer patients during surgical treatment. Eighteen specimens from tumour and 18 normal tissue specimens from colorectal cancer patients at clinical stages III and IV were analysed. The examined patients were divided into two groups; those with BMI greater than or equal to 25 and those with normal BMI. The control group consisted of 18 specimens of non-neoplastic colon tissues, which were divided between overweight/obese and normal body weight patients. The gene transcriptional activity from the specimens was analysed using an oligonucleotide microarray technique. Microarrays and rinsing and marking solutions were prepared according to the procedure in the Gene Expression Analysis Technical Manual. The following conclusions were made: i) change of ADAM28 and IGFBP-3 genes expression are present in the normal tissue in overweight/obese patients with colorectal cancer only; ii) the observed molecular variability of ADAM28 and IGFBP-3 expression may be an initial process of cancer proliferation; iii) the histopathologically normal surgical margin in this group of patients was not equal to the molecular margin.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23527725     DOI: 10.1177/039463201302600122

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  7 in total

1.  Profile of gene expression of TLR-signaling pathways in colorectal cancer tissues.

Authors:  Martyna Bednarczyk; Małgorzata Muc-Wierzgoń; Katarzyna Walkiewicz; Teresa Kokot; Edyta Fatyga; Urszula Mazurek
Journal:  Int J Immunopathol Pharmacol       Date:  2017-06-19       Impact factor: 3.219

Review 2.  The role of some ADAM-proteins and activation of the insulin growth factor-related pathway in colorectal cancer.

Authors:  Katarzyna Walkiewicz; Ewa Nowakowska-Zajdel; Paweł Kozieł; Małgorzata Muc-Wierzgoń
Journal:  Cent Eur J Immunol       Date:  2018-03-30       Impact factor: 2.085

3.  Adamalysines as Biomarkers and a Potential Target of Therapy in Colorectal Cancer Patients: Preliminary Results.

Authors:  Katarzyna Walkiewicz; Joanna Strzelczyk; Dariusz Waniczek; Krzysztof Biernacki; Małgorzata Muc-Wierzgoń; Angelika Copija; Ewa Nowakowska-Zajdel
Journal:  Dis Markers       Date:  2019-09-02       Impact factor: 3.434

4.  Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer.

Authors:  Li Wei; Jing-Yun Wen; Jie Chen; Xiao-Kun Ma; Dong-Hao Wu; Zhan-Hong Chen; Jiang-Long Huang
Journal:  World J Gastroenterol       Date:  2019-10-07       Impact factor: 5.742

5.  Identification of dysregulated miRNAs-genes network in ovarian cancer: An integrative approach to uncover the molecular interactions and oncomechanisms.

Authors:  Sepideh Kadkhoda; Farzaneh Darbeheshti; Javad Tavakkoly-Bazzaz
Journal:  Cancer Rep (Hoboken)       Date:  2020-09-04

6.  The Metalloproteinase ADAM28 Promotes Metabolic Dysfunction in Mice.

Authors:  Lakshini Herat; Caroline Rudnicka; Yasunori Okada; Satsuki Mochizuki; Markus Schlaich; Vance Matthews
Journal:  Int J Mol Sci       Date:  2017-04-21       Impact factor: 5.923

7.  MicroRNA-552 enhances metastatic capacity of colorectal cancer cells by targeting a disintegrin and metalloprotease 28.

Authors:  Jian Wang; Hai Li; Yong Wang; Libin Wang; Xiurui Yan; Dong Zhang; Xiaoqiang Ma; Yong Du; Xiaoming Liu; Yinxue Yang
Journal:  Oncotarget       Date:  2016-10-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.